Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Lung Cancer Diagnosis and Treatment, Esophageal Cancer Research and Treatment, and Lung Cancer Treatments and Mutations.
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study
Association between red blood cell distribution width-to-albumin ratio and prognosis in post-cardiac arrest patients: data from the MIMIC-IV database
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Pembrolizumab in HER2-Positive Gastric Cancer
Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.
LBA-4 Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer
Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in <i>HER2</i>-Mutant Lung Adenocarcinoma